Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) Use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.

2. (Original) Use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of schizophrenia or autism.

3. (Currently Amended) Use according to claim 1 ~~or 2~~, wherein the epothilone is a compound of formula (I):



(I)

wherein:

R^1 represents H, alkyl, alkenyl or alkynyl in C_1-C_6, aryl in C_6-C_{10}, aralkyl in C_7-C_{15},

R^2, R^3 represents each H or form together C=C double bond,

R^4 represents H, C_1-C_6-alkyl in particular CH_3, fluoro substituted C_1-C_6 alkyl in particular CF_3 or CFH_2,

R^5 and R^6 form a C=C double bond or a three membered ring including O, S, NR^7, CR^8R^9 with R^7 being $C(O)R^{10}$, SO_2R^{10} and R^8, R^9, R^{10} being independently H, halogen, C_1-C_6 alkyl, C_6-C_{10} aryl, C_7-C_{15} alkaryl,

R^{11} being H, C_1-C_6 alkyl, C_6-C_{10} aryl, C_7-C_{15} alkaryl, and in particular H,

W represents $C(R^{12})$=CH, $C(R^{12})$=$C(CH_3)$, $C(R^{12})$=CF or a bicyclic aromatic/heteroaromatic radical preferably a 2-methylbenzothiazol-5-yl radical, or a 2-methylbenzoxazol-5-yl radical or a quinolin-7-yl radical, with R^{12} representing a heteroaromatic radical, preferably a 2-pyridinyl, a 2-substituted thiazol-4-yl or a 2-substituted oxazol-4-yl radical with substitution in 2-position by C_1-C_6 alkyl, pseudohalogen like CN or N_3, S-C_1-C_4-alkyl, O-C_1-C_6-alkyl, or C_1-C_6-alkyl substituted by OH, amino, halogen, pseudohalogen such as –NCO, -NCS, $–N_3$, O-(C_1-C_6)-acyl, O-(C_1-C_6)-alkyl or O-benzoyl,

X-Y represents O-C(=O), O-CH_2, CH_2-O, CH_2-C(=O),

Z represents C=O, S, S=O, SO_2,

R^{13} and R^{14} represents independently from each other H, C_1-C_6-alkyl, $(CO)R^{15}$ or C_{1-4}-trialkylsilyl, with R^{15} being H, C_1-C_6-alkyl, fluoro substituted C_1-C_6-alkyl,

and pharmaceutically acceptable salts thereof.

4. (Currently Amended) Use according to ~~any one of claims 1 to 3~~claim 1, wherein the epothilone is a derivative of following formula (II):



(II)

wherein:

R'^{4} represents an C_1-C_6 alkyl or substituted C_1-C_6 alkyl with substituents as F, Cl, Br or I, pseudohalogen, such as –NCO, -NCS , $–N_3$, NH_2, OH, O-(C_1-C_6)-acyl, O-(C_1-C_6)-alkyl or O-benzoyl,

R'^1 and R'^2 are independently from each other H, C_1-C_6-alkyl, (CO)R'^5 with R'^5 being H, C_1-C_6-alkyl, C_1-C_6-fluoroalkyl or C_{1-4}-trialkylsilyl,

R'^3 represents H, C_1-C_6-alkyl, halogen substituted C_1-C_6-alkyl, and

Y and Z form either a C=C double bond or are the O atom of an epoxide and pharmaceutically acceptable salts thereof.

5. (Original) Use according to claim 4, wherein the epothilone is at least a derivative of formula (II) wherein R'^1, R'^2, R'^3 represents independently from each other, H, C_1-C_6-alkyl in particular CH_3, C_1-C_6 fluoroalkyl in particular CF_3 and Y and Z form either a C=C double bond or are together the O atom of an epoxide.

6. (Currently Amended) Use according to ~~any one of claims 1 to 5~~claim 1, wherein epothilone includes at least the natural epothilone A or B of following formula:



Epothilone A



Epothilone B

or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) Use according to ~~any one of claims 1 to 6~~claim 1, wherein epothilone includes at least one synthetic epothilone C, D, E or F of following formula:



Epothilone C



Epothilone D



Epothilone E



Epothilone F

in particular epothilone D and pharmaceutically acceptable salts thereof.

8. (Currently Amended) Use according to ~~any one of claims 1 to 7~~claim 1, wherein epothilone includes at least one synthetic epothilone of following formula:













9. (Currently Amended) Use according to any ~~one of claims 1 to 8~~claim 1, wherein the epothilone(s) is used at a therapeutically effective amount from about 0.01/Kg/dose to about 100 mg/Kg/dose.

10. (Original) Method of treatment of a disease involving a neuronal connectivity defect comprising administering to an individual in need thereof a therapeutic effective amount of one epothilone or derivative thereof.

11. (Original) Method of treatment of a disease involving a neuronal connectivity defect comprising administering to an individual a therapeutically effective amount of at least one epothilone or derivative thereof in a pharmaceutical composition comprising at least a pharmaceutically acceptable carrier.

12. (Currently Amended) Method according to claim 10 ~~or 11~~, wherein the disease includes a psychotic or psychiatric disorder.

13. (Currently Amended) Method according to ~~any one of claims from 10 to 12~~claim 10, wherein the epothilone or pharmaceutical compositions thereof is administered in combination with one or more agents useful in preventing or treating psychotic or psychiatric disorders.

14. (Currently Amended) Method according to ~~any one of claims from 10 to 13~~claim 10, wherein the epothilone is ~~as defined in claims 3 to 9.~~a compound of formula (I):



(I)

wherein:

R^1 represents H, alkyl, alkenyl or alkynyl in C_1-C_6, aryl in C_6-C_{10}, aralkyl in C_7-C_{15},

R^2, R^3 represents each H or form together C=C double bond,

R^4 represents H, C_1-C_6-alkyl in particular CH_3, fluoro substituted C_1-C_6 alkyl in particular CF_3 or CFH_2,

R^5 and R^6 form a C=C double bond or a three membered ring including O, S, NR^7, CR^8R^9 with R^7 being $C(O)R^{10}$, SO_2R^{10} and R^8, R^9, R^{10} being independently H, halogen, C_1-C_6 alkyl, C_6-C_{10} aryl, C_7-C_{15} alkaryl,

R^{11} being H, C_1-C_6 alkyl, C_6-C_{10} aryl, C_7-C_{15} alkaryl, and in particular H,

W represents $C(R^{12})$=CH, $C(R^{12})$=$C(CH_3)$, $C(R^{12})$=CF or a bicyclic aromatic/heteroaromatic radical preferably a 2-methylbenzothiazol-5-yl radical, or a 2-methylbenzoxazol-5-yl radical or a quinolin-7-yl radical, with R^{12} representing a heteroaromatic radical, preferably a 2-pyridinyl, a 2-substituted thiazol-4-yl or a 2-substituted oxazol-4-yl radical with substitution in 2-position by C_1-C_6 alkyl, pseudohalogen like CN or N_3, S-C_1-C_4-alkyl, O-C_1-C_6-alkyl, or C_1-C_6-alkyl substituted by OH, amino, halogen, pseudohalogen such as -NCO, -NCS, -N_3, O-(C_1-C_6)-acyl, O-(C_1-C_6)-alkyl or O-benzoyl,

X-Y represents O-C(=O), O-CH_2, CH_2-O, CH_2-C(=O),

Z represents C=O, S, S=O, SO_2,

R^{13} and R^{14} represents independently from each other H, C_1-C_6-alkyl, $(CO)R^{15}$ or C_{1-4}-trialkylsilyl, with R^{15} being H, C_1-C_6-alkyl, fluoro substituted C_1-C_6-alkyl,

and pharmaceutically acceptable salts thereof.